Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $2.0 million.

  • Summit Therapeutics' Goodwill & Intangibles rose 40.18% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 40.18%. This contributed to the annual value of $1.9 million for FY2024, which is 153.2% down from last year.
  • Summit Therapeutics' Goodwill & Intangibles amounted to $2.0 million in Q3 2025, which was up 40.18% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Goodwill & Intangibles peaked at $13.4 million during Q1 2021, and registered a low of $1.8 million during Q4 2022.
  • For the 5-year period, Summit Therapeutics' Goodwill & Intangibles averaged around $5.6 million, with its median value being $2.0 million (2024).
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first skyrocketed by 340450.0% in 2021, then tumbled by 8550.93% in 2022.
  • Over the past 5 years, Summit Therapeutics' Goodwill & Intangibles (Quarter) stood at $12.4 million in 2021, then tumbled by 85.51% to $1.8 million in 2022, then grew by 5.28% to $1.9 million in 2023, then dropped by 1.53% to $1.9 million in 2024, then increased by 7.24% to $2.0 million in 2025.
  • Its Goodwill & Intangibles was $2.0 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.9 million in Q1 2025.